<DOC>
	<DOCNO>NCT02365610</DOCNO>
	<brief_summary>To investigate potential antiepileptic effect GWP42006 add-on therapy subject inadequately control focal seizure .</brief_summary>
	<brief_title>A Study GWP42006 People With Focal Seizures - Part B</brief_title>
	<detailed_description>This double blind , randomize , placebo control , two-part study . Part B described record . Subjects satisfy inclusion none exclusion criterion enter four-week baseline period , follow two-week dose escalation period ( 400 mg twice daily one week , 600 mg twice daily one week ) , six-week stable treatment period ( 800 mg twice daily ) 12-day taper period . Subjects require attend eight study visit . A follow-up phone call take place four week last dose . Subjects randomize receive 1:1 ratio , GWP42006 placebo . Subjects require record daily diary information seizure , investigational medicinal product ( IMP ) concomitant antiepileptic drug ( AED ) administration .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>For inclusion Part B study patient must fulfil ALL follow criterion : Male female age 18 65 year , inclusive . Welldocumented history focal epilepsy , compatible electroencephalogram clinical history . Documented computerized tomography / magnetic resonance imaging show progressive neurologic abnormality . Has focal seizure despite prior treatment least two AEDs ( whether monotherapies combination ) . Currently treat one three AEDs . All medication intervention epilepsy ( include ketogenic diet ) must stable one month prior screen subject willing maintain stable regimen throughout study . Subject willing keep factor expect affect seizure stable ( level alcohol consumption smoking ) . The patient may enter Part B study ANY follow apply : Time onset focal epilepsy treatment less two year prior enrolment . Patient seizure focal onset . Patient focal seizure without impairment consciousness awareness without observable motor component ( even autonomic component present ) . Episode ( ) status epilepticus one year prior screen . History pseudoseizures . Vagus Nerve Stimulation , Deep Brain Stimulation , Responsive Neurostimulator System epilepsy neurostimulation device implant activate less one year prior screening , and/or stimulation parameter stable less one month , and/or battery life unit anticipated extend duration trial . Had epilepsy surgery within one year screening . Subject clinically significant unstable medical condition epilepsy . Subject illness four week prior screen randomization , epilepsy , opinion investigator would affect seizure frequency . Subject significantly impair hepatic function Visit 1 . Active suicidal plan/intent past six month , history suicide attempt last two year , one lifetime suicide attempt . Subject currently use past use recreational medicinal cannabis , cannabinoid base medication within three month prior screen unwilling abstain duration study . Subject take St John 's Wort last two week and/or unwilling abstain throughout study . Subject consume grapefruit grapefruit juice three day prior randomization and/or unwilling abstain three day prior Visits B2 B7 . Any known suspected hypersensitivity cannabinoids , sesame oil excipients IMP ( ) . Subjects receive IMP within 12 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cannabidivarin</keyword>
	<keyword>CBDV</keyword>
	<keyword>GWP42006</keyword>
</DOC>